Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2004

Study Completion Date

December 31, 2005

Conditions
Crohn Disease
Interventions
DRUG

CCX282-B

Trial Locations (14)

11021

Long Island Clinical Research Associates, LLP, Great Neck

22908

University of Virginia Health System, Digestive Health Center of Excellence, Charlottesville

27612

Wake Forest Research, Raleigh

30342

Atlanta Gastroenterology Associates, Atlanta

37205

Nashville Medical Research Institute, Nashville

38305

Digestive Disease Clinic, Jackson

60637

University of Chicago, Chicago

80104

Rocky Mountain Clincal Research, Golden

80120

Arapahoe Gastroenterology, Littleton

84124

Center for Colon Rectal Disease, Salt Lake City

90048

Cedars-Sinai Medical Center, Los Angeles

Unknown

Mayo Clinic Rochester, Rochester

08009

Comprehensive Clinical Research, Berlin

44106-5066

University Hospitals of Cleveland, Div of Gastroenterology, Cleveland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY